CD4 T-cell exhaustion: does it exist and what are its roles in cancer?
In chronic infections and in cancer, persistent antigen stimulation under suboptimal
conditions can lead to the induction of T-cell exhaustion. Exhausted T cells are …
conditions can lead to the induction of T-cell exhaustion. Exhausted T cells are …
Cancer immunoediting and immune dysregulation in multiple myeloma
K Nakamura, MJ Smyth… - Blood, The Journal of the …, 2020 - ashpublications.org
Avoiding immune destruction is a hallmark of cancer. Over the past few years, significant
advances have been made in understanding immune dysfunction and immunosuppression …
advances have been made in understanding immune dysfunction and immunosuppression …
[HTML][HTML] LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia
C Sordo-Bahamonde, S Lorenzo-Herrero… - Cancers, 2021 - mdpi.com
Simple Summary Patients with chronic lymphocytic leukemia (CLL), the most frequent B cell
malignancy in western countries, develop a progressive immunosuppression, leading to …
malignancy in western countries, develop a progressive immunosuppression, leading to …
[HTML][HTML] Multiple myeloma therapy: emerging trends and challenges
Simple Summary Multiple myeloma (MM) is a frequent hematological malignancy
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …
[HTML][HTML] Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma
J Bae, F Accardi, T Hideshima, YT Tai, R Prabhala… - Leukemia, 2022 - nature.com
Immune profiling in patients with monoclonal gammopathy of undetermined significance
(MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM) provides the …
(MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM) provides the …
[HTML][HTML] Immune-based therapies in the management of multiple myeloma
Multiple myeloma (MM) is a clonal plasma cell malignancy affecting a predominantly elderly
population. The continued development of newer therapies with novel mechanisms of action …
population. The continued development of newer therapies with novel mechanisms of action …
Bispecific T‐cell engagers for treatment of multiple myeloma
Bispecific T cell engagers (TCE) derive from monoclonal antibodies and concomitantly
engage a target on the surface of cancer cell and CD3 on the surface of T‐cells. TCEs …
engage a target on the surface of cancer cell and CD3 on the surface of T‐cells. TCEs …
[HTML][HTML] Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy
Innate immune surveillance of cancer involves multiple types of immune cells including the
innate lymphoid cells (ILCs). Natural killer (NK) cells are considered the most active ILC …
innate lymphoid cells (ILCs). Natural killer (NK) cells are considered the most active ILC …
[HTML][HTML] NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
M Bachiller, L Perez-Amill, AM Battram… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Chimeric antigen receptor (CAR)-T cell immunotherapy has modified the
concept of treatment in hematological malignancies. In comparison with pediatric patients …
concept of treatment in hematological malignancies. In comparison with pediatric patients …
Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma
H Parmar, M Gertz, EI Anderson, S Kumar… - Blood …, 2021 - ashpublications.org
The immediate postautologous stem cell transplant (ASCT) period in multiple myeloma
represents a unique opportunity for long-term disease control because many patients have …
represents a unique opportunity for long-term disease control because many patients have …